CTRV vs. GRI, NBSE, GLMD, PBLA, DRMA, CMRA, INM, PRFX, QLGN, and LSDI
Should you be buying ContraVir Pharmaceuticals stock or one of its competitors? The main competitors of ContraVir Pharmaceuticals include GRI Bio (GRI), NeuBase Therapeutics (NBSE), Galmed Pharmaceuticals (GLMD), Panbela Therapeutics (PBLA), Dermata Therapeutics (DRMA), Comera Life Sciences (CMRA), InMed Pharmaceuticals (INM), PainReform (PRFX), Qualigen Therapeutics (QLGN), and Lucy Scientific Discovery (LSDI). These companies are all part of the "medical" sector.
GRI Bio (NASDAQ:GRI) and ContraVir Pharmaceuticals (NASDAQ:CTRV) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability, community ranking and earnings.
GRI Bio has a beta of -1.77, suggesting that its share price is 277% less volatile than the S&P 500. Comparatively, ContraVir Pharmaceuticals has a beta of 1.16, suggesting that its share price is 16% more volatile than the S&P 500.
ContraVir Pharmaceuticals received 219 more outperform votes than GRI Bio when rated by MarketBeat users.
34.0% of GRI Bio shares are owned by institutional investors. Comparatively, 1.1% of ContraVir Pharmaceuticals shares are owned by institutional investors. 16.8% of GRI Bio shares are owned by insiders. Comparatively, 1.6% of ContraVir Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, GRI Bio had 1 more articles in the media than ContraVir Pharmaceuticals. MarketBeat recorded 1 mentions for GRI Bio and 0 mentions for ContraVir Pharmaceuticals. ContraVir Pharmaceuticals' average media sentiment score of 0.23 beat GRI Bio's score of 0.00 indicating that GRI Bio is being referred to more favorably in the media.
ContraVir Pharmaceuticals' return on equity of -795.54% beat GRI Bio's return on equity.
Summary
GRI Bio beats ContraVir Pharmaceuticals on 5 of the 9 factors compared between the two stocks.
Get ContraVir Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for CTRV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CTRV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ContraVir Pharmaceuticals Competitors List
Related Companies and Tools
